Johnson & Johnson (JNJ)
| Market Cap | 398.39B |
| Revenue (ttm) | 90.63B |
| Net Income (ttm) | 22.66B |
| Shares Out | 2.41B |
| EPS (ttm) | 9.33 |
| PE Ratio | 17.74 |
| Forward PE | 15.19 |
| Dividend | $5.20 (3.14%) |
| Ex-Dividend Date | Aug 26, 2025 |
| Volume | 1,481,121 |
| Open | 165.48 |
| Previous Close | 164.74 |
| Day's Range | 164.95 - 166.59 |
| 52-Week Range | 140.68 - 169.99 |
| Beta | 0.40 |
| Analysts | Buy |
| Price Target | 173.00 (+4.58%) |
| Earnings Date | Jul 16, 2025 |
About X
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizo... [Read more]
Financial Performance
In 2024, Johnson & Johnson's revenue was $88.82 billion, an increase of 4.30% compared to the previous year's $85.16 billion. Earnings were $14.07 billion, a decrease of -59.99%.
Financial StatementsAnalyst Summary
According to 15 analysts, the average rating for JNJ stock is "Buy." The 12-month stock price target is $173.0, which is an increase of 4.58% from the latest price.
News
Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 3% Dividend Yields
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high...
Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb
Former FDA Commissioner Dr. Scott Gottlieb joins 'Squawk Box' to discuss news of President Trump ordering pharma companies to lower U.S. drug prices in the next 60 days, the move to tiered pricing glo...
President Trump demands drugmakers slash prices within 60 days
CNBC's Joe Kernen reports on the latest news.
Pharma Companies Should Immediately Cut Down Drug Prices, Trump Says
President Donald Trump demanded several pharmaceutical companies cut down their drug prices for American consumers Thursday, issuing a Sept. 29 deadline for the businesses to “end the free ride of Ame...
Trump says he asked 17 drugmakers to take steps to cut U.S. prices within 60 days.
President Donald Trump on Thursday said he asked major pharmaceutical companies to take steps to cut U.S. drug prices within the next 60 days.
Trump pressures 17 pharma CEOs to cut US drug prices
U.S. President Donald Trump sent letters to the chief executives of 17 major pharmaceutical companies, urging immediate action to lower the cost of prescription drugs for Americans, the White House sa...
Trump posts letters to 17 pharmaceutical companies about drug prices
CNBC's Angelica Peebles joins 'The Exchange' to discuss President Trump posting letters to 17 pharmaceutical companies about drug prices.
Trump says he asked 17 drugmakers to take steps to cut U.S. prices within 60 days
President Donald Trump said he asked major pharmaceutical companies to take steps to cut U.S. drug prices within the next 60 days. It comes after Trump in May signed an executive order reviving a cont...
Johnson & Johnson to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will present at the Morgan Stanley 23rd Annual Global Healthcare Conference on Wednesday, September 10th, 2025. Management will part...
Boston Jury Hits Johnson & Johnson with Record $42M Verdict in Asbestos Baby Powder Case
BOSTON--(BUSINESS WIRE)--A Boston jury has sided with Paul and Kathryn Lovell in a lawsuit against cosmetic behemoth Johnson & Johnson (NYSE:JNJ) that asserted Mr. Lovell's mesothelioma was directly c...
Johnson & Johnson Launches VIRTUGUIDE™ AI-Powered Patient-Matched Lapidus System in U.S. to Reduce Complexity in Bunion Surgery for Millions
Early VIRTUGUIDE™ surgeons report a 30-minute reduction in surgical time versus traditional treatment1 ,2 , *,** WEST CHESTER, Penn. , July 29, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) – Joh...
Johnson & Johnson files with U.S. FDA to include new evidence in TREMFYA® (guselkumab) label as the only IL-23 inhibitor to demonstrate significant inhibition of joint structural damage in active psoriatic arthritis
Submission is supported by 24-week results from the Phase 3b APEX study in adults with active psoriatic arthritis treated with TREMFYA ® , the only dual-acting IL-23 inhibitor HORSHAM, Pa. , July ...
22 Dividend Kings At Discounted Valuations
Dividend kings can offer reliable income growth and capital appreciation, making them attractive for long-term investors. During our screening today, we have 22 dividend kings trading at what could be...
20 Kiplinger July Dividend Favorites: No Cigars
Dividend stocks are regaining appeal as interest rates fall, offering higher returns and lower risk compared to non-dividend payers over the long term. Top Kiplinger dividend 'dogs' are projected to d...
3 Pharma Stocks That Aren't Sweating the Coming 200% Drug Tariffs
On July 8, US President Donald Trump shook the biopharmaceutical sector by announcing a tariff of up to 200% on pharmaceuticals, which would take effect “very soon.” 80% of prescription drugs sold in ...
US FDA says J&J's Ethicon issues correction related to surgical stapler
The U.S. drug regulator said on Friday Ethicon Endo-Surgery, a unit of Johnson & Johnson , issued a correction for certain lots of a part related to its surgical stapler and classified the action as "...
Johnson & Johnson to Participate in the 2025 Wells Fargo Healthcare Conference
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will present at the 2025 Wells Fargo Healthcare Conference on Wednesday, September 3rd, 2025. Management will participate in a Fires...
How To Build A $100,000 Dividend Portfolio: Targeting A Yield Of 15%+ In 20 Years
The Dividend Income Accelerator Portfolio delivers a 3.98% yield and 7.11% five-year dividend growth, balancing income and growth for strong risk-adjusted returns. Our portfolio is globally diversifie...
Johnson & Johnson Stock Could Be Waking Up
Johnson & Johnson's stock appears undervalued, as sluggish revenue growth and margin contraction are offset by raised full-year guidance and a rebounding outlook. Both Innovative Medicine and MedTech ...
Best Dividend Kings: July 2025
14 Dividend Kings continue to outperform the S&P 500 in 2025. Dividend growth remains healthy, with one recent increase and a collective 2025 growth rate of 5.23%. Seventeen Dividend Kings currently a...
Insider report: These stocks had the biggest sales by executives in the past week
Some investors follow company insiders on the notion that they would know better than anyone when it's the right time to buy or sell shares. CNBC rounded up some of the biggest sales over the last wee...
Johnson & Johnson seeks first icotrokinra U.S. FDA approval aiming to revolutionize treatment paradigm for adults and adolescents with plaque psoriasis
Icotrokinra is a first-in-class investigational targeted oral peptide that selectively blocks the IL-23 receptor Filing based on unprecedented data package that met all primary endpoints across four P...
Jim Cramer explains why Johnson & Johnson rallied after 'surprise' earnings results
As Wall Street navigates a jam-packed start to earnings season, CNBC's Jim Cramer explained what made shares of Johnson & Johnson rise after the company posted its quarterly report. "Sometimes in this...
JNJ gave us a manual on how to spot a stock that can soar after earnings, says Jim Cramer
'Mad Money' host Jim Cramer talks how to react when surprise stock pops happen.
Stock Of The Day: Breakout In Johnson & Johnson
Johnson & Johnson JNJ stalled out at resistance around the $165 level. There tends to be resistance at price levels that had previously been resistance.